CHIMERIC THERAPEUTICS LIMITED — Director's Dealing 2022

Nov 23, 2022

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001. Amended 01/01/11

	Chimeric Therapeutics Limited (ASX: CHM)
Name of Entity:
	68 638 835 828
ABN:

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Jennifer Chow
Date of Last Notice:	14 December 2021

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or Indirect Interest		Direct and Indirect	Direct and Indirect	Direct and Indirect	Direct and Indirect	Direct and Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevantinterest.		Held via Employee Share Trust
Date of change		18 November 2022
No. of securities held prior to change					Options 10,291,495 - 10,291,495
			Shares		Options
		Direct	1,702,914		10,291,495
		Indirect	-		-
		**Total **	1,702,914		10,291,495
Class		a) Fully Paid Ordinary Shares b) Unlisted Options
Number acquired						Options b) 17,222,368 - 17,222,368
				Shares		Options
		Direct				b) 17,222,368
		Indirect		a)4,338,990		-
		Total		4,338,990		17,222,368
Number disposed						Options - - -
				Shares		Options
		Direct		-		-
		Indirect		-		-
		Total		-		-

• See chapter 19 for defined terms.

Appendix 3Y Page 1

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation		a) $0.092 per share b) Non-cash, see ‘nature of change’ below.	a) $0.092 per share b) Non-cash, see ‘nature of change’ below.	a) $0.092 per share b) Non-cash, see ‘nature of change’ below.
No. of securities held after change			Shares Options 1,702,914 27,514,133 4,338,990 - 6,041,904 27,513,863
			Shares	Options
		Direct	1,702,914	27,514,133
		Indirect	4,338,990	-
		**Total **	6,041,904	27,513,863
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back		a) and b) Issue of shares and options as approved by Chimeric Therapeutics Limited shareholders at the Annual General Meeting held on 15 November 2022.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relationto whichtheinteresthas changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – Closed period

art 3 – Closed period
Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

==> picture [39 x 23] intentionally omitted <==

The CFO Solution

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011